PEDIATRICS Vol. 48 No. 4 October 1971, pp. 556-561
This Article
Right arrow Full Text (PDF)
Right arrow P3Rs: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when P3Rs are posted
Right arrow Alert me if a correction is posted
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Yeung, C. Y.
Right arrow Articles by Yu, V. Y. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Yeung, C. Y.
Right arrow Articles by Yu, V. Y. H.

PHENOBARBITONE ENHANCEMENT OF BROMSULPHALEIN CLEARANCE IN NEONATAL HYPERBILIRUBINEMIA

C. Y. Yeung M.B., B.S., M.R.C.P. (Edin.), M.R.C.P. (Glasg.), D.C.H.1 and Victor Y. H. Yu M.B., B.S.1

1 Department of Pediatrics, University of Hong Kong

Forty jaundiced Chinese newborn infants were randomly assigned to treatment and control groups. Twenty infants in the former group were given phenobarbitone 5 mg 8-hourly; those in the control group received no drug. BSP tests were performed in all infants on admission and repeated 24 hours afterwards. The percentage disappearance of the dye at designated intervals up to 135 minutes of each test before and after drug therapy was compared with that of the controls. Rate constants for the hepatic uptake phase (K1) and the biliary excretory phase (K2) in BSP removal were calculated from the plasma dye disappearance graph.

Following phenobarbitone therapy, a significant increase in BSP clearance was observed, with increases in K1 and K2 values, suggesting the corresponding enhanced hepatic uptake and excretion of the dye.

These results are consistent with the hypothesis that several mechanisms together are responsible for the phenobarbitone effect on the impaired liver function of newborn infants. It is suggested that the observed reduction of serum bilirubin levels with phenobarbitone therapy results both from enhanced uptake and from increased excretion of bilirubin by the liver.

Submitted on December 22, 1970
Accepted on March 8, 1971